Literature DB >> 719462

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

E K Perry, B E Tomlinson, G Blessed, K Bergmann, P H Gibson, R H Perry.   

Abstract

Necropsy brain tissue from normal (control) patients and patients with depression and dementia was examined for activities of various cholinergic components, and these related to the degree of senile plaque formation and extent of intellectual impairment. Choline acetyltransferase and acetylcholinesterase activities decreased significantly as the mean plaque count rose, and in depressed and demented subjects the reduction in choline acetyltransferase activity correlated with the extent of intellectual impairment as measured by a memory information test; muscarinic cholinergic receptor binding activity remained unchanged with increasing senile plaque formation but butyrylcholinesterase activity increased. The results suggest a close relation between changes in the cholinergic system and Alzheimer's dementia, but the precise role of the system in this disease remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 719462      PMCID: PMC1608703          DOI: 10.1136/bmj.2.6150.1457

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  20 in total

1.  The amnesic properties of hyoscine and atropine in pre-anaesthetic medication.

Authors:  T K HARDY; D WAKELY
Journal:  Anaesthesia       Date:  1962-07       Impact factor: 6.955

2.  Brain-decarboxylase activities as indices of pathological change in senile dementia.

Authors:  D M Bowen; P White; R H Flack; C B Smith; A N Davison
Journal:  Lancet       Date:  1974-06-22       Impact factor: 79.321

3.  Observations on the brains of demented old people.

Authors:  B E Tomlinson; G Blessed; M Roth
Journal:  J Neurol Sci       Date:  1970-09       Impact factor: 3.181

4.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

5.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

6.  Clinical effects of choline in Alzheimer senile dementia.

Authors:  W D Boyd; J Graham-White; G Blackwood; I Glen; J McQueen
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

7.  Cholinesterase inhibition in treatment of Alzheimer's dementia.

Authors: 
Journal:  Lancet       Date:  1978-03-25       Impact factor: 79.321

8.  Clinical effects of choline in Alzheimer's disease.

Authors:  P Etienne; S Gauthier; G Johnson; B Collier; T Mendis; D Dastoor; M Cole; H F Muller
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

9.  The 'compartmentation' of choline acetyltransferase within the synaptosome.

Authors:  F Fonnum
Journal:  Biochem J       Date:  1967-04       Impact factor: 3.857

10.  Neocortical cholinergic neurons in elderly people.

Authors:  P White; C R Hiley; M J Goodhardt; L H Carrasco; J P Keet; I E Williams; D M Bowen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

View more
  277 in total

1.  The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.

Authors:  C Weiss; A R Preston; M M Oh; R D Schwarz; D Welty; J F Disterhoft
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 2.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

3.  Drugs for Alzheimer's disease.

Authors:  J T O'Brien; C G Ballard
Journal:  BMJ       Date:  2001-07-21

Review 4.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

5.  Tacrine for Alzheimer's disease. Costs and benefits.

Authors:  D Knopman
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 6.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

Review 7.  Traumatic brain injury as a risk factor for Alzheimer's disease: a review.

Authors:  T C Lye; E A Shores
Journal:  Neuropsychol Rev       Date:  2000-06       Impact factor: 7.444

8.  Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.

Authors:  L Preda; M Alberoni; S Bressi; C Cattaneo; J Parini; N Canal; M Franceschi
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Effects of disrupting the cholinergic system on short-term spatial memory in rats.

Authors:  J S Andrews; J H Jansen; S Linders; A Princen
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

10.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.

Authors:  B J Sahakian; A M Owen; N J Morant; S A Eagger; S Boddington; L Crayton; H A Crockford; M Crooks; K Hill; R Levy
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.